David De Vries
About David De Vries
David De Vries is a Co-Founder and Chief Operating Officer at Tr1X, where he focuses on engineering cures for autoimmune diseases. He has extensive experience in research and development, having previously worked at institutions such as UCLA Medical Center, The Scripps Research Institute, and RAND Corporation.
Current Role at Arine
David De Vries serves as a Co-Founder at Arine, a position he has held since 2017. Based in the San Francisco Bay Area, Arine focuses on improving healthcare outcomes through innovative technology solutions. De Vries has contributed to the strategic direction and operational management of the company, leveraging his extensive background in health and biotechnology.
Current Role at Tr1X
Since 2021, David De Vries has been the Co-Founder and Chief Operating Officer at Tr1X. In this role, he is involved in engineering cures for autoimmune diseases using proprietary technology that emphasizes the scalable generation of Treg cells. His leadership aims to address significant medical needs within this field.
Previous Experience in Healthcare Research
David De Vries has a diverse background in healthcare research. He worked as a Research Assistant at UCLA Medical Center for three months in 2009 and at The Scripps Research Institute for three months in 2008. Additionally, he served as an Associate at RAND Corporation in RAND Health from 2012 to 2015, where he contributed to health policy research.
Educational Background
David De Vries studied at the University of Cambridge, where he earned a Master of Philosophy in Chemical Engineering and Biotechnology (Bioscience Enterprise). He also attended Harvard University, achieving an A.B. in Neurobiology, Global Health, and Health Policy. His education has provided a strong foundation for his work in the healthcare sector.
Work History Overview
David De Vries has held various roles in the healthcare and biotechnology sectors. He worked at Proteus Digital Health, Inc. in Commercial Development and Strategy from 2016 to 2018, and at Komaza as an Operations Associate in 2010. He also worked as an Associate Researcher at the Salk Institute for Biological Studies for five months in 2010-2011.